IL10 inversely correlates with the percentage of CD8+ cells in MDS patients

Leukemia Research

Volumn 37, Issue 5, 2013, Pages 541-546

  Lopes, Matheus Rodrigues ^a   Traina, Fabiola ^a   Campos, Paula de Melo ^a   Pereira, João Kleber Novais ^a   Machado Neto, João Agostinho ^a   Machado, Helymar da Costa ^a   Gilli, Simone Cristina Olenscki ^a   Saad, Sara Teresinha Olalla ^a   Favaro, Patricia ^a,b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CD8+ cells; IL10; Immune System; Myelodysplastic Syndrome

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HEMOGLOBIN; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGE; AGED; ARTICLE; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CTLA4 GENE; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; FOXP3 GENE; GRANULOCYTE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INTERLEUKIN 10 GENE; KARYOTYPING; LYMPHOCYTOPENIA; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; PATHOGENESIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; SEX DIFFERENCE; TGFBETA1 GENE; THROMBOCYTE COUNT; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-10; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84875906562     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.01.019     Document Type: Article

References (51)

1. Deeg H.J., Beckham C., Loken M.R., Bryant E., Lesnikova M., Shulman H.M., Gooley T. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma 2000, 37:405-414.
2. Mufti G., List A.F., Gore S.D., Ho A.Y. Myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program 2003, 176-199.
3. Parker J.E., Mufti G.J. Ineffective hematopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol 1998, 101:220-230.
4. Parker J.E., Mufti G.J. Excessive apoptosis in low risk myelodysplastic syndromes (MDS). Leuk Lymphoma 2000, 40:1-24.
5. Parker J.E., Mufti G.J., Rasool F., Mijovic A., Devereux S., Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000, 96:3932-3938.
6. Barrett A.J., Sloand E. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica 2009, 94:449-451.
7. Aggarwal S., van de Loosdrecht A.A., Alhan C., Ossenkoppele G.J., Westers T.M., Bontkes H.J. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol 2011, 153:568-581.
8. Kotsianidis I., Bouchliou I., Nakou E., Spanoudakis E., Margaritis D., Christophoridou A.V., Anastasiades A., Tsigalou C., Bourikas G., Karadimitris A., Tsatalas C. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 2009, 23:510-518.
9. Ortega J., List A. Immunomodulatory drugs in the treatment of myelodysplastic syndromes. Curr Opin Oncol 2007, 19:656-659.
10. Greenberg P.L., Young N.S., Gattermann N. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2002, 136-161.
11. Molldrem J.J., Caples M., Mavroudis D., Plante M., Young N.S., Barrett A.J. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997, 99:699-705.
12. Killick S.B., Mufti G., Cavenagh J.D., Mijovic A., Peacock J.L., Gordon-Smith E.C., Bowen D.T., Marsh J.C. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 2003, 120:679-684.
13. Fozza C., Longinotti M. Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?. Eur J Haematol 2012, 88:380-387.
14. Kordasti S.Y., Ingram W., Hayden J., Darling D., Barber L., Afzali B., Lombardi G., Wlodarski M.W., Maciejewski J.P., Farzaneh F., Mufti G.J. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007, 110:847-850.
15. Zou J.X., Rollison D.E., Boulware D., Chen D.T., Sloand E.M., Pfannes L.V., Goronzy J.J., Bai F., Painter J.S., Wei S., Cosgrove D., List A.F., Epling-Burnette P.K. Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia 2009, 23:1288-1296.
16. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
17. Tabachnick B.G., Fidell L.S. Using Multivariate Statistics 2001, Allyn and Bacon, Boston, p. 111-176.
18. Yoshida Y., Stephenson J., Mufti G.J. Myelodysplastic syndromes: from morphology to molecular biology. Part I. Classification, natural history and cell biology of myelodysplasia. Int J Hematol 1993, 57:87-97.
19. Bogdanovic A.D., Trpinac D.P., Jankovic G.M., Bumbasirevic V.Z., Obradovic M., Colovic M.D. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia 1997, 11:656-659.
20. Nilsson L., Astrand-Grundstrom I., Arvidsson I., Jacobsson B., Hellstrom-Lindberg E., Hast R., Jacobsen S.E. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000, 96:2012-2021.
21. Shioi Y., Tamura H., Yokose N., Satoh C., Dan K., Ogata K. Increased apoptosis of circulating T cells in myelodysplastic syndromes. Leuk Res 2007, 31:1641-1648.
22. Nimer S.D. MDS: a stem cell disorder - but what exactly is wrong with the primitive hematopoietic cells in this disease?. Hematology Am Soc Hematol Educ Program 2008, 43-51.
23. Bynoe A.G., Scott C.S., Ford P., Roberts B.E. Decreased T helper cells in the myelodysplastic syndromes. Br J Haematol 1983, 54:97-102.
24. Hamblin T.J. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 1996, 33:150-162.
25. Hamblin T. Immunologic abnormalities in myelodysplastic syndromes. Hematol Oncol Clin North Am 1992, 6:571-586.
26. Amin H.M., Jilani I., Estey E.H., Keating M.J., Dey A.L., Manshouri T., Kantarjian H.M., Estrov Z., Cortes J.E., Thomas D.A., Giles F.J., Albitar M. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood 2003, 102:1866-1868.
27. Chan A.C., Neeson P., Leeansyah E., Tainton K., Quach H., Prince H.M., Godfrey D.I., Ritchie D., Berzins S.P. Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients. Leukemia 2010, 24:592-600.
28. Hamada K., Takahashi I., Matsuoka M., Saika T., Mizobuchi N., Yorimitsu S., Takimoto H. Apoptosis of peripheral leukocytes in patients with myelodysplastic syndromes. Rinsho Ketsueki 1998, 39:1079-1084.
29. Matsutani T., Yoshioka T., Tsuruta Y., Shimamoto T., Ohyashiki J.H., Suzuki R., Ohyashiki K. Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. Leuk Res 2003, 27:305-312.
30. Epling-Burnette P.K., Painter J.S., Rollison D.E., Ku E., Vendron D., Widen R., Boulware D., Zou J.X., Bai F., List A.F. Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia 2007, 21:659-667.
31. Fozza C., Contini S., Galleu A., Simula M.P., Virdis P., Bonfigli S., Longinotti M. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp Hematol 2009, 37:947-955.
32. Kook H., Zeng W., Guibin C., Kirby M., Young N.S., Maciejewski J.P. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 2001, 29:1270-1277.
33. Sloand E.M., Melenhorst J.J., Tucker Z.C., Pfannes L., Brenchley J.M., Yong A., Visconte V., Wu C., Gostick E., Scheinberg P., Olnes M.J., Douek D.C., Price D.A., Barrett A.J., Young N.S. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood 2011, 117:2691-2699.
34. Maciejewski J.P., Risitano A., Sloand E.M., Nunez O., Young N.S. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 2002, 99:3129-3135.
35. Sloand E.M., Mainwaring L., Fuhrer M., Ramkissoon S., Risitano A.M., Keyvanafar K., Lu J., Basu A., Barrett A.J., Young N.S. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005, 106:841-851.
36. Chamuleau M.E., Westers T.M., van Dreunen L., Groenland J., Zevenbergen A., Eeltink C.M., Ossenkoppele G.J., van de Loosdrecht A.A. Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome. Haematologica 2009, 94:496-506.
37. Meers S., Vandenberghe P., Boogaerts M., Verhoef G., Delforge M. The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: a single centre study of 131 patients. Leuk Res 2008, 32:1026-1035.
38. Symeonidis A., Kourakli A., Katevas P., Perraki M., Tiniakou M., Matsouka P., Georgoulias V., Zoumbos N. Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis. Eur J Haematol 1991, 47:277-281.
39. Hamdi W., Ogawara H., Handa H., Tsukamoto N., Murakami H. Clinical significance of Th1/Th2 ratio in patients with myelodysplastic syndrome. Int J Lab Hematol 2009, 31:630-638.
40. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
41. Hahn B.H., Singh R.P., La Cava A., Ebling F.M. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. J Immunol 2005, 175:7728-7737.
42. 8+ T cells that protect from lupus-like disease. J Immunol 2010, 185:6563-6571.
43. Frisullo G., Nociti V., Iorio R., Plantone D., Patanella A.K., Tonali P.A., Batocchi A.P. CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients. Hum Immunol 2010, 71:437-441.
44. + regulatory T cells and suppress Th2 immune responses during allergen immunotherapy. J Immunol 2010, 184:7229-7237.
45. + T cells from renal transplant recipients in quiescence induce immunoglobulin-like transcripts-3 and -4 on dendritic cells from their respective donors. Transplant Proc 2007, 39:3065-3067.
46. 3+ regulatory T cells. Am J Transplant 2012, 12:2335-2347.
47. Fozza C., Longu F., Contini S., Galleu A., Virdis P., Bonfigli S., Murineddu M., Gabbas A., Longinotti M. Patients with Early-Stage Myelodysplastic Syndromes Show Increased Frequency of CD4+CD25+CD127(low) Regulatory T Cells. Acta Haematol 2012, 128:178-182.
48. Kordasti S.Y., Afzali B., Lim Z., Ingram W., Hayden J., Barber L., Matthews K., Chelliah R., Guinn B., Lombardi G., Farzaneh F., Mufti G.J. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009, 145:64-72.
49. Alfinito F., Sica M., Luciano L., Pepa R.D., Palladino C., Ferrara I., Giani U., Ruggiero G., Terrazzano G. Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes. Br J Haematol 2009, 148:90-98.
50. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
51. Kang S.S., Allen P.M. Priming in the presence of IL-10 results in direct enhancement of CD8+ T cell primary responses and inhibition of secondary responses. J Immunol 2005, 174:5382-5389.